cole
dale
p
van
dolleweerd
cj
isitt
v
et
al
regulatori
approv
firstinhuman
phase
clinic
trial
monoclon
antibodi
produc
transgen
tobacco
plant
plant
biotechnol
j
excel
case
studi
learn
histor
develop
plantderiv
hivneutr
monoclon
antibodi
enter
clinic
phase
clinic
evalu
prove
safe
well
toler
healthi
women
administ
intravagin
hweisan
loh
brian
j
green
product
protein
plant
human
health
applic
becom
attract
strategi
attribut
potenti
lowcost
product
increas
safeti
due
lack
human
anim
pathogen
scalabl
abil
produc
complex
protein
major
mileston
plantbas
protein
product
use
human
health
achiev
protalix
biotherapeut
produc
taligluceras
alfa
elelyso
suspens
cultur
transgen
carrot
cell
line
treatment
patient
gaucher
diseas
approv
usa
food
drug
administr
review
highlight
variou
approach
plantbas
product
protein
recent
progress
develop
plantmad
therapeut
biolog
prevent
treatment
human
diseas
infecti
diseas
remain
one
lead
caus
mortal
morbid
develop
countri
exacerb
lack
resourc
infrastructur
prevent
treat
control
diseas
therefor
emerg
reemerg
pathogen
frequent
result
epidem
countri
past
sever
decad
product
protein
plant
shown
promis
approach
manufactur
target
human
health
applic
plant
compar
product
system
offer
advantag
includ
eas
scale
lack
human
anim
pathogen
tabl
review
focus
sever
approach
use
produc
protein
plant
prophylact
therapeut
applic
combat
human
diseas
condit
variou
approach
plantbas
product
protein
illustr
figur
stabl
nuclear
chloroplast
transform
two
approach
util
express
heterolog
recombin
protein
plant
agrobacteriummedi
stabl
transform
long
histori
plant
genet
manipul
achiev
stabl
integr
tdna
plant
nuclear
genom
howev
approach
time
consum
lead
time
rang
month
typic
low
level
target
protein
express
stabl
introduct
target
gene
chloroplast
genom
chloroplast
transform
transplastom
howev
allow
higher
level
target
express
compar
nuclear
transform
larg
due
lack
gene
silenc
high
gene
copi
number
technic
difficult
lack
posttransl
modif
success
limit
number
plant
speci
transient
express
target
protein
plant
use
modifi
plant
virus
viral
vector
integr
binari
vector
deliv
via
agrobacterium
often
consid
robust
approach
compar
stabl
transform
due
rapid
product
capabl
rel
high
protein
express
major
plant
viral
vector
use
date
base
singlestrand
rna
virus
tobacco
mosaic
viru
potato
viru
x
cowpea
mosaic
viru
cpmv
encod
least
three
protein
function
viral
replic
replicas
encapsid
coat
protein
movement
celltocel
movement
protein
initi
strategi
involv
product
recombin
protein
use
plant
virus
exploit
natur
abil
infect
full
viru
plant
howev
approach
gener
fail
due
instabl
viral
genom
modifi
introduct
larg
target
gene
issu
larg
resolv
use
agrobacteriummedi
gene
deliveri
agroinfiltr
target
gene
either
directli
clone
agrobacterium
vector
modifi
plant
viral
vector
integr
agrobacterium
binari
plasmid
deliv
plant
tissu
infiltr
transform
agrobacterium
agroinfiltr
allow
high
level
target
protein
express
tabl
gener
comparison
express
host
product
heterolog
protein
medic
pharmaceut
applic
potenti
costeffect
product
peak
protein
express
typic
observ
less
day
postinfiltr
significantli
faster
compar
full
viru
strategi
requir
week
order
gener
system
infect
express
promis
platform
evidenc
numer
success
clinic
trial
demonstr
safeti
efficaci
plantmad
protein
therapeut
biolog
exampl
respond
influenza
viru
pandem
occur
medicago
canadian
compani
report
produc
vaccin
candid
hemagglutinin
day
nicotiana
benthamiana
agroinfiltr
provid
rapid
respons
capabl
current
prefer
approach
product
protein
plant
modifi
plant
virus
treatment
human
diseas
loh
green
yusibov
detect
serum
igg
immun
mice
sc
fecal
iga
immun
mice
via
oral
administr
hepat
b
viru
hbv
small
surfac
antigen
shbsag
evlp
vaccin
hbv
lactuca
sativa
lettuc
transgen
nuclear
detect
serum
igg
immun
mice
via
oral
administr
hbv
surfac
antigen
hbsag
suv
hbv
solanum
tuberosum
potato
transgen
nuclear
induct
serum
antibodi
stabl
immunolog
memori
immun
mice
fed
transgen
potato
tuber
human
immunodefici
viru
hiv
multiepitop
envelop
protein
lettucetransgen
nuclear
detect
cellmedi
humor
immun
immun
mice
via
oral
administr
hiv
multiepitop
envelop
protein
multihiv
tobaccotransgen
chloroplast
detect
antibodi
cellular
respons
well
specif
ifng
product
immun
mice
via
oral
administr
envelop
protein
evlp
vaccin
purifi
increas
level
insulin
secret
pancreat
cell
oral
feed
lyophil
lower
blood
glucos
level
mice
key
abbrevi
ade
antibodydepend
enhanc
c
h
constant
domain
immunoglobulin
heavi
chain
c
l
constant
domain
immunoglobulin
light
chain
ctb
cholera
toxin
b
cvlp
chimer
viruslik
particl
diii
domain
iii
dpp
dipeptidyl
peptidas
e
envelop
evlp
envelop
viruslik
particl
ex
exendin
f
coagul
factor
gaa
acid
alpha
glucosidas
glp
glucagon
like
peptid
gp
glycoprotein
ha
hemagglutinin
hi
hemagglutinationinhibit
hc
heavi
chain
ig
immunoglobulin
ltb
heatlabil
enterotoxin
b
subunit
im
intramuscular
intranas
ip
intraperiton
iv
intraven
mab
monoclon
antibodi
n
nucleocapsid
pa
protect
antigen
rtb
ricin
toxin
b
sag
surfac
antigen
sc
subcutan
scfv
singlechain
variabl
fragment
immunoglobulin
suv
subunit
vaccin
vlp
viruslik
particl
numer
exampl
plantproduc
protein
target
prophylact
therapeut
applic
subsect
vaccin
antibodi
biopharmaceut
preclin
develop
shown
tabl
sever
lead
candid
gone
clinic
trial
tabl
comprehens
review
vaccin
highli
effect
tool
prevent
infect
last
three
decad
plantproduc
antigen
target
variou
pathogen
shown
effect
anim
model
tabl
sever
candid
progress
earli
stage
clinic
develop
evalu
phase
human
clinic
trial
tabl
planet
biotechnolog
hayward
ca
produc
world
first
plantderiv
clinic
test
secretori
iga
monoclon
antibodi
recogn
surfac
antigen
iii
streptococcu
mutan
carorx
tm
predominantli
caus
dental
cari
follow
success
demonstr
safeti
efficaci
phase
clinic
trial
carorx
tm
licens
europ
medic
devic
categori
appli
oral
topic
solut
prevent
tooth
decay
recombin
human
growth
hormon
first
plantbas
biopharmaceut
protein
produc
plant
two
decad
later
fda
may
approv
elelyso
human
recombin
taligluceras
alfa
glucocerebrosidas
enzym
produc
genet
engin
carrot
cell
treat
type
gaucher
diseas
gd
protalix
biotherapeut
partner
pfizer
gd
lysosom
storag
disord
caus
hereditari
defici
enzym
glucocerebrosidas
gcd
gd
current
treat
enzym
replac
therapi
use
recombin
gcd
administ
intraven
everi
week
addit
offer
versatil
product
platform
numer
plantmad
protein
plant
virus
engin
provid
medic
applic
way
vlp
offer
advantag
recombin
protein
vaccin
tend
elicit
higher
immun
respons
viru
nanoparticl
also
develop
target
deliveri
diseas
treatment
diagnost
purpos
exampl
cpmv
repres
icosahedr
nanoparticl
capsid
surfac
display
access
lysin
residu
conjug
variou
chemic
moieti
like
fluoresc
dyesarray
polyethylen
glycol
polym
subcellular
target
molecul
use
technolog
includ
engin
viral
resist
construct
cpmv
nanoparticl
display
gastrinreleas
peptid
receptor
overexpress
human
prostat
cancer
anoth
exampl
cowpea
chlorot
mottl
viru
stabli
assembl
vitro
packag
rna
deriv
sindbi
viru
mammalian
viru
hybrid
cowpea
chlorot
mottl
virusbas
vlp
shown
protect
rna
degrad
cellular
nucleas
abl
deliv
releas
rna
content
within
cytoplasm
mammalian
cell
moreov
hybrid
vlp
fusion
subcellular
target
moieti
could
direct
toward
distinct
site
within
cell
potenti
appli
medic
target
deliveri
tool
plant
virus
also
engin
act
adjuv
elicit
immun
respons
potent
effect
rodshap
papaya
mosaic
viru
nanoparticl
engin
express
influenza
epitop
surfac
mice
ferret
immun
recombin
nanoparticl
exhibit
increas
robust
humor
respons
influenza
viru
infect
grow
evid
plant
capabl
make
protein
desir
qualiti
address
rang
human
healthrel
issu
plant
product
platform
protein
therapeut
biolog
particular
transient
agroinfiltr
approach
demonstr
abil
use
broad
research
develop
well
commerci
need
extens
discuss
transient
agroinfiltr
approach
ideal
platform
fast
scalabl
product
respons
new
outbreak
highli
infecti
diseas
demonstr
variou
program
success
protalix
biotherapeut
gain
fda
approv
therapeut
enzym
elelyso
human
use
signific
mileston
plant
molecular
pharm
field
importantli
primari
benefit
plantmad
protein
therapeut
biolog
term
product
safeti
potenti
costeffect
contribut
global
public
health
develop
develop
nation
yao
j
weng
yq
dickey
wang
yj
plant
factori
human
pharmaceut
applic
challeng
int
j
mol
sci
paper
illustr
plant
molecular
farm
pharm
concept
relat
human
pharmaceut
applic
sever
type
plantbas
product
platform
describ
challeng
planttyp
glycosyl
downstream
bioprocess
biosafeti
concern
also
discuss
besid
preclin
clinic
studi
enlist
review
paper
elabor
